Affiliation:
1. SVKM’S NMIMS, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, V.L. Mehta Road, Vile Parle West, Mumbai-400056, India
Abstract
Background:
The only conclusive way to diagnose Alzheimer’s is to carry out brain
autopsy of the patient’s brain tissue and ascertain whether the subject had Alzheimer’s or any other
form of dementia. However, due to the non-feasibility of such methods, to diagnose and conclude
the conditions, medical practitioners use tests that examine a patient’s mental ability.
Objective:
Accurate diagnosis at an early stage is the need of the hour for initiation of therapy. The
cause for most Alzheimer’s cases still remains unknown except where genetic distinctions have
been observed. Thus, a standard drug regimen ensues in every Alzheimer’s patient, irrespective of
the cause, which may not always be beneficial in halting or reversing the disease progression. To
provide a better life to such patients by suppressing existing symptoms, early diagnosis, curative
therapy, site-specific delivery of drugs, and application of hyphenated methods like artificial intelligence
need to be brought into the main field of Alzheimer’s therapeutics.
Methods:
In this review, we have compiled existing hypotheses to explain the cause of the disease,
and highlighted gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics and
quantum dots as advancements in the existing strategies to manage Alzheimer’s.
Conclusion:
Biomarkers, brain-imaging, and theranostics, along with artificial intelligence, are
understood to be the future of the management of Alzheimer’s.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology,General Medicine
Cited by
340 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献